Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
March 07, 2024 08:00 ET
|
Interpace Biosciences, Inc.
●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and...
Interpace Biosciences Announces Path Forward in Letter to Shareholders
February 16, 2021 21:21 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to...